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ABSTRACT 
Background:  Contact immunotherapy with diphencyprone (DCP) is used in the management of alopecia 
areata (AA). The treatment, given weekly, induces dermatitis and requires a prolonged treatment course 
RYHUPRQWKV5HSRUWHGHIILFDF\LVYDULDEOHDQGDQLQGLYLGXDO¶VUHVSRQVHFDQQRWFXUUHQWO\EHDFFXUDWHO\
predicted.  
Objective: Identify patient and treatment course variables that may affect outcome to DCP treatment. 
Methods We performed a retrospective review of patient data from our DCP service over a 20-year 
period from 1991-2010, including patient and treatment course variables, with the aim of identifying 
factors relevant to treatment outcome.  
Results Complete data was available for 205 treatment courses. 162 (79%) treatment courses were 
completed for 133 patients. Overall, 72.2% (96/133) of completed treatment courses resulted in some 
degree of hair re-growth (any grade). In 15.8% (21/133) of completed courses, hair growth response 
was >90% re-growth. However, 27.1% (36/133) of courses resulted in no hair growth response. During a 
further 13.5% (18/133) of courses, a response to DCP was obtained initially but patients relapsed during 
treatment. We found extent of alopecia at baseline and duration of disease to be statistically significant 
when comparing those with an optimal outcome with those who did not (p<0.05). In contrast to other 
reports, we found variables such as atopy, age at onset of disease and the presence of nail changes 
were not of statistical significance with regard to outcome. For patients receiving more than one course 
of treatment, response to DCP treatment tended to be broadly consistent for each treatment course. 
DCP was generally well tolerated with 43% of patients reporting no side effects. However, 5.9% (12/205) 
of DCP treatment courses were terminated early due to side effects. Cervical lymphadenopathy was the 
most common side effect (39%). 
Limitations of this study include that this was a retrospective study and the lack of long term follow up 
looking at relapse. 
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Conclusion Our findings add to published data on DCP outcome, assisting clinicians and patients in the 
decision as to whether to undertake a course of DCP treatment and show that extent of alopecia at 
baseline and duration of disease are important factors in predicting response to treatment. 
 
Key Words:  alopecia areata, diphencyprone, DCP, immunotherapy 
 
Capsule Summary: 
What is already known on this topic: 
x There is a lack of robust evidence for many of the treatments used in AA. 
x Spontaneous re-growth occurs in 34-50% 
x Treatment with immunotherapy results in widely varied response rates 
x Patient and treatment variables may predict outcome to immunotherapy 
 
What this article adds to our knowledge: 
x More extensive AA at baseline predicts poorer response to treatment. 
x Longer duration of disease at baseline predicts poorer response to treatment 
x Atopy should not be considered a negative prognostic factor  
x Patients receiving more than one course of treatment have similar response to treatment in 
subsequent courses 
x Failure to respond to one treatment course should not preclude a further trial. 
 
How this information impacts clinical practice and or changes patient care: 
x This study provides us with further information with can be provided to patients considering 
undertaking a course of DCP including likelihood of response 
x This study also provides insight into outcome for those patients who may which to have further 
treatments. 
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INTRODUCTION 
Alopecia areata (AA) is considered to be a CD8+ T-cell dependent organ specific autoimmune disorder 
affecting the hair follicle1 with a clinical disease spectrum ranging from limited patchy scalp hair loss to 
complete loss of scalp and body hair. Commonly used treatments include topical and intra-lesional 
corticosteroids, dithranol and topical immunotherapy.2 The mechanism of action of immunotherapy using 
diphencyprone (DCP) is unclear but has been described as an immune-deviation strategy.1 The protocol 
for DCP contact immunotherapy in alopecia areata was first described by Happle in 1983.3 He reported 
50% of patients had some response to treatment, with a cosmetically acceptable result in 29%. 
Subsequent reports reveal widely variable treatment responses (9-85% complete response rates).4 
Possible explanations for these variations in response include definition of treatment response, disease 
duration and severity, and duration of treatment. We reviewed 20 years data on DCP treatment courses 
for AA in Glasgow with an aim of identifying predictors of treatment outcome. 
 
 
METHODS 
Medical and nursing caserecords were reviewed for patients commencing treatment with DCP between 
January 1991 and December 2010. Data recorded included age at start of treatment; age at disease 
onset; gender; history of atopy (asthma, allergic rhinitis and atopic eczema); evidence of nail changes; 
baseline severity of hair loss (graded 1-5: 1-limited patchy; 2±extensive patchy; 3±subtotal scalp hair 
loss; 4±alopecia totalis; 5±alopecia universalis; or diffuse loss)  as per MacDonald-Hull;5 duration of 
alopecia; previous treatments; number of DCP treatments; concentrations of DCP used; patient-reported 
inflammatory response (1 - nil, 2 - barely perceptible, 3 - mild, 4 - moderate 5 - intense, 6 - very intense) 
and treatment response (0 ± no hair growth; 1 - vellus hair growth; 2 -  sparse terminal pigmented hair; 3 
± pigmented terminal hair re-growth but some persistent patches of alopecia; 4 - 90-99% hair re-growth; 
5 - complete re-growth; grade 6: any response followed by relapse). An optimal outcome was defined by 
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outcome groups 4 and 5 (i.e. >90% hair re-growth). In addition, for the period 2001-2010, side effects 
recorded during treatment were documented.  
Data for patients receiving more than one treatment course during the 20 year period were included only 
once for statistical analysis (first course only). This group were reviewed separately to assess 
reproducibility of DCP response over multiple treatment courses. 
All patients had a clinical diagnosis of alopecia areata made by a consultant dermatologist and/or by a 
consultant in a tertiary referral hair clinic. All patients were treated with topical DCP according to a 
standard protocol. This consisted of sensitisation with 2% DCP on the scalp (if DCP naïve) followed by 
weekly treatments with DCP. The aim was to induce an eczematous reaction consisting of erythema and 
pruritus persisting for 48 hours. Initially, half the scalp was treated. If hair growth was observed, the 
entire scalp would be treated. There was some flexibility regarding end point of treatment course, 
however treatment would be discontinued in the following situations: if no hair growth was achieved after 
6 months treatment; at full re-growth (if occurring before 6 months); when no further re-growth could be 
obtained despite treatment or at patient request. 
Statistical Analysis: Factors possibly related to outcome were compared between those with an optimal 
treatment response (grade4&5) and those without (grade0-3 and grade6). These between-group 
comparisons were done using t-test or Mann-Whitney tests for numerical variables, and chi-squared for 
categorical variables. All analyses were done using Minitab (version 16) at a 5% significance level.  
 
This retrospective review of data did not require institutional review board / human subjects committee 
approval but was registered with the local audit, research and development committee. 
 
 
RESULTS 
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In the 20-year-period from 1991-2010, 253 treatment courses were undertaken, with available data on 
205. Of 205 treatment courses, 162 were completed on 133 patients (18 patients received 2 courses; 2 
patients received 3 courses; 1 patient received 4 courses; 1 patient received 5 courses). 
Forty-three courses (21%) were not completed. This represents a dropout rate of 1 in 5. All patients 
dropping out after sensitisation or after less than 5 sessions were classed as incomplete and therefore 
excluded from the analysis. Reasons for discontinuation included failure to attend/unknown (19/205 
courses); social reasons (12/205 courses) and treatment side effects (12/205 courses). No patients were 
found to be DCP anergic. 
 
Patient data 
Patient demographics, baseline clinical information and treatment data are shown in table I and figure 1. 
Most patients had tried more than one treatment before referral for DCP, however 8.3% (11/133) had no 
previous treatment. Patients trying DCP as a first line treatment tended to have more severe AA at 
baseline (63.4% [7/11] grade 4/5/diffuse).  
 
Response to Treatment 
Treatment course information for the cohort is summarised in table 1. With respect to treatment 
response, 36/133 (27.1%) had no response to treatment, 27/133 (20.3%) developed vellus hair, 8/133 
(6.0%) developed sparse pigmented hair, 22/133 (16.5%) developed terminal re-growth with patchy 
alopecia, 7/133 (5.3%) developed 90-99% re-growth and 14/133 (10.5%) patients developed complete 
re-growth (figure 2). Final treatment outcome was unrecorded for 1 patient. In 18/133 (13.5%) courses, 
initial hair re-growth was followed by significant hair loss during treatment.  
 
Patient and Treatment variables 
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Differences in outcome with respect to patient and treatment variables are shown in tables IIa-c. For 
statistical analysis, course outcomes were categorised as optimal response (>90% re-growth: groups 4 
& 5) and non-optimal response (groups 0-3 and group 6). 
Those with an optimal response were found to have had a significantly lower median duration of disease 
than those without (2 years vs. 4.5 years, p=0.046). There was also a significant association between 
baseline disease extent and optimal response (p=0.003). Those with grade 1 AA were more likely to 
have an optimal response and those with grade 3-5 are less likely (figure III). All the other variables 
were not significant, as shown in table IId. 
 
Side effects 
Treatment side effects in the cohort of patients treated between 2001-2010 (n=95) were documented. 
Additionally, those experienced by patients that did not complete the course were reviewed. Overall 
5.9% (12/205) of treatment courses were terminated early due to side effects. 
No side effects were reported in 42/95 patients (44%). Mild eczema outwith the scalp was reported 
during 17/95 treatments (18%) and severe eczema (defined as blistering, weeping, +/- widespread 
secondary sensitisation) occurred in 11/95 treatments (12%). Cervical lymphadenopathy was the 
commonest side effect reported in 37/95 patients (39%). Headache occurred in 14/95 (15%) treatments, 
and otalgia in 2/95 (2%) patients. 
Other side effects included flare of a facial acneiform eruption; postinflammatory hyperpigmentation of 
the scalp and 2 cases of severe peri-orbital / facial swelling. Both the latter cases occurred at or shortly 
after sensitisation with 2% DCP. In both cases, a moderate (therapeutic) dermatitic scalp reaction to 
DCP was associated with severe periorbital and facial oedema requiring a course of oral prednisolone. 
Whether the facial swelling represented a type 1 reaction to DCP is uncertain.  Neither patient continued 
with treatment. 
 
Relapse 
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Data on relapse following completion of treatment was not routinely documented however, those 
patients relapsing during treatment following an initial response, were recorded. In total, 18/133 (13.5%) 
patients achieved initial hair re-growth but then lost hair during treatment. In addition, 22 patients had 
more than one course of DCP during the 20 year study period (18 patients had 2 courses, 2 patients had 
3 courses, 1 patient had 4 courses, 1 patient had 5 courses [n = 51 courses]). The median grade for 
disease extent in this group was extensive patchy. The mean time between the end of one course and 
start of next course was 16 months (median 14 months). 20 patients had consistent responses to DCP 
in all courses. 19 had re-growth in all courses, 1 no re-growth in all courses. Thus 91% (20/22) showed 
consistent responses to DCP treatment. However, for 2 patients who had a dissimilar response, both 
responded poorly in the first course but were treated successfully in a second course.  
  
 
DISCUSSION 
Spontaneous re-growth in patchy localised AA is estimated to occur in 34-50% of patients.2 However, 
patients with more extensive disease often wish to pursue treatment and topical immunotherapy has 
been recommended as a first line treatment option if locally available.2 The allergic contact dermatitis 
caused by DCP is thought to attenuate the T-cell mediated immune reaction against the hair bulb 
allowing re-growth of the hair.7  
It is not possible to accurately predict an individual`s response to immunotherapy with DCP. Before 
committing to an often prolonged treatment course, in addition to the uncertainty of treatment response, 
patients must consider factors such as the impact of once weekly hospital attendance for a minimum 6-
month period, strict photo-protection of the scalp for 48 hours after treatment and a heightened scrutiny 
of, and emotional response to, hair gain and loss. 
Patient and treatment variables have been reported as being relevant in response to DCP treatment.5, 8-
13 With the aim of providing better information on outcome for both clinician and patient in making the 
decision to embark on DCP treatment, we reviewed 20 years data on DCP treatment courses. The 
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variables assessed included baseline severity of hair loss, disease duration, the presence of atopy, nail 
changes and hair growth response.  
The DCP service has been provided in our Department for over 20 years and has run in conjunction with 
a dedicated Hair Clinic for the last 14 years, with a small cohort of doctors and nursing staff. Given the 
small numbers of clinic staff since the service began (5 experienced senior nurses) documentation and 
interpretation of patient responses has been consistent. This DCP service appears to be one of the 
larger services provided in the UK and is perhaps one of the few services with as yet no reported cases 
of staff sensitisation due to strict protocols for protective clothing worn by clinical and pharmacy staff. 
Additionally this appears to be one of the larger cohorts of patients receiving DCP treatment performed 
to date.8-13 Limitations of this study include use of retrospective data and limited longterm follow up with 
respect to disease relapse. 
 
Cohort characteristics appear broadly similar to those of other studies. The median age of our group 
(33.5 years) and gender split (74% female) is similar to that of several other large studies .10, 13 Mean 
duration of disease (6.8 years) is similar to studies by El- Zawahry (6.61 years), Ohlmeier (6 years) and 
Wiseman (9.6 years)  thus  our group is comparable  in terms of disease chronicity.  
Atopy was present in 36.1% of patients, similar to numbers reported in several other larger DCP 
studies10, 13 and in keeping with current European data on atopy prevalence in the general population,15 
but significantly higher than observed by El-=DZDKU\¶VJURXS11 
We suspect the documentation of nail changes in this study (18.8%) may have been an overestimation 
as this parameter was recorded only in nursing documentation and may have included changes other 
than pitting and trachonychia, possibly explaining the lack of significance with respect to outcome 
compared with other studies.8,9 Other studies have documented nail changes ranging from 12.6%11 to 
33.0%13 of patients receiving DCP and are thought to occur in around 10% of areata patients.2 
No patients were found to be anergic in contrast with other studies which quote rates of anergy in 
immunotherapy ranging from 5-19%.10, 16-18  Reasons for this  finding are unclear.  
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With respect to patient variables predicting outcome, we found both baseline severity of hair loss 
(p=0.003) and duration of disease (p=0.043) to be significant similar to Van der Steen and Weise et al.8,9 
However both these authors and others have found variables in addition to disease severity and 
duration of disease to be significant.5, 10-13  Atopy coincident with AA is postulated to be associated with a 
poorer disease prognosis20, 21 and possibly a worse outcome with DCP treatment.9, 12 However, in 
common with Wiseman et al13 our study did not find atopy to be of statistical significance with regard to 
outcome. The criteria by which patients were considered to be atopic has varied between studies: while 
we included a history of hayfever, childhood asthma or eczema as consistent with atopy, other studies 
looked only at atopic eczema and outcome.9  
 
Many studies, including this, have found gender to be unimportant in predicting outcome.4 The greater 
proportion of women completing treatment in our cohort (74.4%) and others may reflect the cosmetic 
impact of AA in women and a greater desire for treatment.10, 13 
 
Treatment variables such as requiring higher concentrations of DCP to maintain an inflammatory 
response have also been thought to be an unfavorable prognostic factor.9, 13, 22 However, this was not 
true of our cohort. While optimal responders (n=21) required a median concentration of DCP of 0.025% 
to maintain an inflammatory response compared with 0.01% for non-optimal responders (n=111), this 
was not statistically significance. It has been suggested that if a higher DCP concentration is required to 
achieve active inflammation this may signify greater difficulty inducing sufficient cytokine and 
inflammatory mediator release required to induce hair growth.13 The greater concentration used in the 
optimal response group cannot be explained by differences in treatment course length (median no. 
treatments for both was 27).  A further intriguing finding was that all groups had the same median 
median inflammatory responses (grade 4) suggesting factors additional to induction and maintenance of 
inflammation are important in inducing hair re-growth.  
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Comparisons between published studies can be difficult. While an optimal response of 15.8% may 
appear low, this may relate to definition of optimal response.8, 10, 11, 13 In this study, optimal response was 
defined as >90% re-growth. Other studies have used a variety of definitions of optimal response ranging 
from >75% re-growth,11 13 to less well defined criteria such as ³VXEWRWDORUWRWDOUH-JURZWK´8 In addition, 
there may be variation in disease severity at baseline: achieving >90% re-growth in a patient with limited 
patchy disease may not be directly comparable, in terms of treatment success, with baseline AA totalis 
achieving >90% re-growth. The largest group in this study were those with severe loss at baseline 
(totalis/universalis n=53 [39.8%]). Other studies have involved more individuals with less severe 
disease. Ohlmeier et al reported complete response rates of 37.8% but only 17.8% had 
totalis/universalis at baseline.10  
 
A drop out rate of 1 in 5 (43/205 [21%]) perhaps reflects the prolonged commitment to treatment 
required of patients. As we offer treatment to individuals from a wide geographic area, this commitment 
may involve long journeys on a weekly basis and patients may dropout sooner as a result. Dropout due 
to side effects was 5.9% [12/205], broadly similar to other centres. Ohlmejer et al found 1.5% of patients 
(2/135) discontinued therapy due to side effects.10 In our cohort, cervical lymphadenopathy was the 
commonest side effect reported in 37/95 patients (39%), significantly higher than 2% incidence in some 
studies13 but similar to others (50%).11 Additionally, we identified 2 patients with a possible Type I 
reaction to DCP, a phenomenon rarely reported.23, 24 It has been suggested that this may be dose-
dependent, with patients able to continue treatment without side effects at a lower doses. We also report 
2 cases of severe peri-orbital / facial swelling which occurred at or shortly after sensitisation with 2% 
DCP and required treatment with oral prednisolone. In both, this was associated with only a moderate 
(therapeutic) dermatitic scalp reaction to DCP. Whether the facial swelling represented a type 1 reaction 
to DCP is uncertain however, neither patient wished to continue  treatment.  A further unusual side effect 
not previously reported was the development of an acneiform facial eruption in a 41-year-old man after 
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21 treatments with DCP. There was a history of facial acne previously, however this had been entirely 
settled prior to DCP treatment being commenced. The eruption settled following a 3-month course of 
oral minocycline and cessation of DCP therapy.  
 
 
Although we lack long-term follow up data for the majority of patients, 22 patients received multiple 
courses of DCP over the 20 year period (n=51 courses). This group achieved a mean remission period 
of 16 months between courses.  Of those receiving more than one treatment course, 91% of patients 
had a broadly similar response to DCP with each treatment course (19 had re-growth in all courses, 1 
had no re-growth in all courses). While our department has not offered on-going maintenance therapy 
for individuals who have successfully completed a course of DCP treatment, this is recommended by 
some centres.11. 19, 22, 25, However, the benefit of this strategy has been questioned. 13, 22 Given the 
continuity of response observed in repeat courses it would be interesting to assess hether DCP 
maintenance would result in a more prolonged remission compared with no maintenance therapy and 
further study of the role of maintenance therapy is warranted. For the two patients who had a dissimilar 
response, both responded poorly in the first course but were treated successfully in the second course. 
Thus, a poor initial response should not necessarily preclude a second trial of DCP treatment  
 
CONCLUSIONS: 
We found extent of alopecia at baseline and duration of disease are predictors of outcome, findings 
which may assist patients in the decision to commit to undertaking DCP treatment. Atopy was not found 
to be a negative predictive factor and should not preclude trial of treatment. We recognise the need for 
improved follow up and now send questionnaires to all patients completing successful courses 1 year 
after completion of treatment. Further studies assessing maintenance therapy are required. Additionally 
in the group not responding despite adequate immune response/inflammation, further comparative 
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studies may help elucidate the immunological mechanisms by which DCP immune deviation permits hair 
re-growth. 
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Figure 1: Distribution of severity of hair loss at baseline (n=133) 
The figure shows that the distribution of severity of hair loss in this group is weighted 
towards the more severe end of the spectrum in AA, with only 19% (25/133) having 
limited patchy disease and 77% (103/133) with extensive patchy, subtotal hair loss, 
alopecia totalis or alopecia universalis. 
 
Figure 2: Response to treatment in those completing the course.  
Figure showing an optimal outcome (complete re-growth or 90-99% re-growth) was 
achieved in 16% (21/133) of patients completing the course of DCP. However 27% of 
patients had no response (36/133) to treatment. 
 
Figure 3: Severity of Hair Loss at Baseline and Outcome 
Figure showing that fewer patients with severe hair loss at baseline (alopecia totalis 
and universalis) appear to achieve an optimal response (shaded in red in the figure) 
after treatment compared with those with less severe hair loss at baseline (limited 
patchy AA).
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Table I: Patient Demographics, Clinical and Treatment Data of whole cohort (n=133) 
 
Demographic data  
Number of treatment courses with available data 205 
Number of completed treatment courses 162 
Number of patients completing course 133 
Number of incomplete treatment courses  43 
Gender of those competing treatment course:            Female 99/133 (74.4%) 
                                                                                     Male 34/133 (25.6%) 
Age at beginning of treatment (years)  
                                                                                       Mean 35 
                                                                                      Median 33.5 
                                                                                      Range 13-69 
Clinical Data  
History of Atopy 48/133 (36.1%) 
Nail changes 25/133 (18.8%) 
Severity of AA at baseline (fig. 1):  
                                                            Limited patchy 25/133 (18.8%) 
                                                            Extensive patchy 35/133 (26.3%) 
                                                            Subtotal hair loss 15/133 (11.3%) 
                                                            AA Totalis 33/133 (24.8%) 
                                                            AA Universalis 20/133 (15.0%) 
                                                            Diffuse AA 3/133 (2.3%) 
                                                            Unknown/Undefined 2/133(1.5%) 
  
Disease Duration at baseline:                Mean 6.8 years 
                                                            > 10 years 37/133 (27.8%) 
                                                            < 1 year 25/133 (18.8%) 
                                                            > 1 year and < 10 years 68/133 (51.1%) 
                                                               Unknown 3/133 (2.3%) 
Treatment Data  
Average number of treatments per course 34 
Range 10-115 
Median median concentration of DCP used 0.01%. 
Median median inflammation achieved 4 
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Table IIa: Table showing patient variables Age and Sex in each response group 
 
 
 
 
 
Table IIb: Table showing treatment variables in each response group: 
 
 
 All patients  
completing 
treatment 
course 
Any Response 
(grade 1-6) 
n= 96/133 
No response 
(grade 0) 
n= 36/133 
Optimal response 
(>90% growth: 
grade 4&5) 
n= 21/133 
Non-Optimal 
Response 
(grade 0-3 
and grade 6) 
n= 111/133 
Mean Number 
of treatments 
per course 
 
34 
 
 
37 
 
 
25 
 
 
34 
 
 
34 
Median number 
of treatments 
per course 
 
27 
 
27 
 
23 
 
27 
 
27 
Median median 
% DCP 
 
0.01% 
 
 
0.01% 
 
 
0.0025% 
 
 
0.025% 
 
 
0.0100% 
Median grade of 
inflammation (1-
6) 
 
 
4 
 
 
4 
 
 
4 
 
 
4 
 
 
4 
 
 
 
 
 
 
 All patients  
completing 
treatment course  
Any response   
(grade 1-6)  
No response  
 
Optimal 
response  
(>90% re-
growth: grade 
4+5)  
Non-Optimal 
Response 
(grade 0-3 and 
grade 6) 
 
Number of 
patients 
  
133 
 
96 (72%) 
 
36 (27.1%) 
 
21 (15.8%) 
 
111 (83.5%) 
 
Median Age 
(years) 
 
33.5 
 
30 
 
37 
 
34 
 
33 
 
Females 
 
 
99/133 
(74%) 
 
71/96 
(74%) 
 
27/36 
(75%) 
 
14/21 
(67%) 
 
84/111 
(75.7%) 
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Table IIc: Table showing patient variables in each response group 
 
Patient Variable Any Response 
(Grade 1-6) 
n = 96/133 
No Response 
(Grade 0) 
n = 36/133 
 
Optimal Response 
(Grade 4 & 5) 
n = 21/133 
 
Non-Optimal 
Response (grade 
0-3 and grade 6) 
n= 111/133 
Atopic  
 
Non-DWRSLF  
32/48 (66.6%) 
 
59/79 (70%) 
16/48 (33.3%) 
 
19/79 (24.1%)  
7/48 (14.6%) 
 
12/79 (15.2%) 
41/48 (85.4%) 
 
66/79 (83.5%) 
Severity of Alopecia§ 
 
x Alopecia 
Universalis/ 
Totalis 
 
x Mild AA 
 
 
 
34/53 (64%)  
 
 
 
19/25 (76%) 
 
 
 
19/53 (35.8%) 
 
 
 
6/25 (24.0%) 
 
 
4/53 (7.5%) 
 
 
 
9/25 (36.0%) 
 
 
 
49/53 (92.5%) 
 
 
 
16/25 (64.0%) 
Length of time ZLWK$$Á 
 
x >10 yrs 
 
x <1 yr 
 
 
 
28/37 (75%) 
 
18/25 (72%) 
 
 
9/37 (24.3%) 
 
7/25 (28.0%) 
 
 
3/37 (8.1%) 
 
6/25 (24.0%) 
 
 
34/37 (91.9%) 
 
19/25 (76.0%) 
 
Nail Changes 
 
 
17/25 (68%) 
 
8/25 (32.0%) 
 
5/25 (20.0%) 
 
 
20/25 (80%) 
$WRSLFVWDWXVRISDWLHQWVXQNQRZQDQGQRQ-atopic patient had an unknown 
outcome, § 1/133 patients had an unknown severity of hair loss and 1 patient with 
WRWDOLVXQLYHUVDOLVKDGDQXQNQRZQRXWFRPHÁKDGDQXQNQRZQGLVHDVH
duration.  nail changes unknown for 75 patients. 
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Table IId: Statistical analysis of patient and treatment variables: optimal vs. non-
optimal response  
 
* Denotes statistically significant results 
 
 
 
 
 
Patient Variable Statistical test used p value 
Age Mann-Whitney p = 0.932 
Age at Onset Mann-Whitney p = 0.966 
Gender Pearson Chi-Square p = 0.397 
Extent of disease* Pearson Chi-Square p = 0.003*  
Those with JUDGH
loss are less likely to 
have an optimal outcome 
Duration of disease* Mann-Whitney p = 0.046* 
Those with the optimal 
response had a 
significantly lower 
median duration of 
disease 
Atopy Pearson Chi-Square p = 0.903 
Nail Changes Pearson Chi-Square p = 0.906 
Treatment Variable   
Median Strength of DCP Mann-Whitney p = 0.386 
Median Inflammatory Response Pearson Chi-Square p = 0.358 
Total Number of treatments Mann-Whitney p = 0.794 
